Kiadis announces presentations at the 2020 ASH Annual Meeting and Exposition
13 Novembro 2020 - 3:00AM
Kiadis announces presentations at the 2020 ASH Annual Meeting and
Exposition
Amsterdam, The Netherlands, November 13,
2020 – Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext
Amsterdam and Brussels: KDS), a clinical-stage
biopharmaceutical company developing innovative NK-cell-based
medicines for the treatment of life-threatening diseases, today
announces that five abstracts related to its K-NK-cell therapy
platform were accepted for presentation at the 62nd American
Society of Hematology (ASH) Annual Meeting and Exposition being
held virtually from December 5-8, 2020.
The ASH abstracts are now available online through the ASH
conference website at
www.hematology.org/Annual-Meeting/Abstracts/.
Details of the oral presentation are as
follows:
- Oral Presentation #68: Haploidentical MbIL-21
Ex Vivo Expanded NK Cells (FC21-NK) for Patients with Multiple
Relapsed and Refractory Acute Myeloid
LeukemiaPresenter: Piyanuch Kongtim,
MDAffiliation: MD Anderson Cancer Center, Houston,
TXSession: 704. Immunotherapies: Beyond T to
NKPresentation Date: Saturday, December 5, 2020:
8:45 AM
Details of the poster presentations are as follows:
- Poster #825: Optimizing Ex-vivo Expanded NK
Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC)
Combined With NKTR-255 in Chronic Lymphocytic Leukemia (CLL),
Follicular Lymphoma (FL), and Burkitt Lymphoma
(BL)Presenter: Yaya
ChuAffiliation: New York Medical College,
Valhalla, NYSession: 203. Lymphocytes, Lymphocyte
Activation, and Immunodeficiency, including HIV and Other
Infections: Poster IPresentation Date: Saturday,
December 5, 2020: 7:00 AM-3:30 PM Poster Hall
- Poster #2151: A Phase I Trial of Incorporating
Natural Killer (K-NK) Cells for Patients with Chronic Myeloid
Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase
Inhibitor (TKI) Therapy Presenter: Lindsay Rein,
MDAffiliation: Duke University Medical Center,
Durham, NCSession: 632. Chronic Myeloid Leukemia:
Therapy: Poster IIPresentation Date: Sunday,
December 6, 2020: 7:00 AM-3:30 PM, Poster Hall
- Poster #2341: BMT CTN 1803: Haploidentical
Natural Killer Cells (K-NK002) to Prevent Post-Transplant Relapse
in AML and MDS (NK-REALM) Presenter: Sumithira
Vasu, MDAffiliation: The Ohio State University,
Columbus, OHSession: 703. Adoptive Immunotherapy:
Mechanisms and New Approaches: Poster IIPresentation
Date: Sunday, December 6, 2020: 7:00 AM-3:30 PM, Poster
Hall
- Poster #2347: A Phase I Clinical Trial Testing
the Safety of IL-21-Expanded, Off-the-Shelf, Third-Party Natural
Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and
Myelodysplastic SyndromePresenter: Sumithira
VasuAffiliation: The Ohio State University,
Columbus, OHSession: 704. Immunotherapies: Poster
IIPresentation Date: Sunday, December 6, 2020:
7:00 AM-3:30 PM, Poster Hall
Dutch Translation/Nederlandse
vertaling
Kiadis Pharma N.V.
(“Kiadis”) is een Nederlands beursgenoteerd
biotechbedrijf in de klinische fase dat nieuwe geneesmiddelen
ontwikkelt tegen ernstige ziekten. Het maakt daarbij gebruik van
Natural Killer-cellen (NK-cellen), grote witte bloedlichamen die de
eerste verdedigingslinie in het menselijk afweersysteem vormen
tegen kankercellen en infecties. Kiadis maakt dat vijf ‘abstracts’
over het K-NK-celtherapieplatform zijn geaccepteerd voor
presentatie op de 62e American Society of Hematology (ASH) Annual
Meeting and Exposition die virtueel wordt gehouden van 5 tot 8
december 2020.
De ASH-samenvattingen zijn nu online beschikbaar via de
ASH-conferentiewebsite op
www.hematology.org/Annual-Meeting/Abstracts/.
Details van de presentaties zijn als volgt:
- Poster #2151: Een fase I-onderzoek naar het
opnemen van Natural Killer-cellen (K-NK) voor patiënten met
chronische myeloïde leukemie (CML) en moleculaire restziekte na
therapie met tyrosinekinaseremmers
(TKI)Presentator: Lindsay Rein, MDGelieerd
aan: Duke University Medical Center, Durham,
NCSessie: 632. Chronische myeloïde leukemie:
therapie: poster IIPresentatiedatum: zondag 6
december 2020: 7:00 - 15:30 uur, Posterzaal
- Mondelinge presentatie #68: Haplo-identieke
MbIL-21 ex vivo geëxpandeerde NK-cellen (FC21-NK) voor patiënten
met meervoudige recidiverende en refractaire acute myeloïde
leukemiePresentator: Piyanuch Kongtim,
MDGelieerd aan: MD Anderson Cancer Center,
Houston, TXSessie: 704. Immuuntherapie: voorbij T
tot NKPresentatiedatum: zaterdag 5 december 2020:
8.45 uur
- Poster #825: Optimalisatie van ex-vivo
geëxpandeerde NK-celgemedieerde antilichaamafhankelijke cellulaire
cytotoxiciteit (ADCC) gecombineerd met NKTR-255 bij chronische
lymfatische leukemie (CLL), folliculair lymfoom (FL) en Burkitt
lymfoom (BL)Presentator: Yaya ChuGelieerd
aan: New York Medical College, Valhalla,
NYSessie: 203. Lymfocyten, lymfocytactivering en
immunodeficiëntie, inclusief hiv en andere infecties: poster
IPresentatiedatum: zaterdag 5 december 2020: 07:00
- 15:30 uur Posterzaal
- Poster #2341: BMT CTN 1803: Haploidentical
Natural Killer Cells (K-NK002) ter voorkoming van terugval na
transplantatie bij AML en MDS
(NK-REALM)Presentator: Sumithira Vasu,
MDGelieerd aan: The Ohio State University,
Columbus, OHSessie: 703. Adoptieve immunotherapie:
mechanismen en nieuwe benaderingen: poster
IIPresentatiedatum: zondag 6 december 2020: 7:00 -
15:30 uur, Posterzaal
- Poster #2347: Een fase I klinisch onderzoek
naar de veiligheid van IL-21-uitgebreide, off-the-shelf natural
killer-cellen van derden voor recidiverende/refractaire acute
myeloïde leukemie en myelodysplastisch
syndroomPresentator: Sumithira
VasuGelieerd aan: The Ohio State University,
Columbus, OHSessie: 704. Immuuntherapie: Poster
IIPresentatiedatum: zondag 6 december 2020: 7:00 -
15:30 uur, Posterzaal
Dit persbericht vormt een samenvatting
van het gepubliceerde Engelstalige persbericht. Bij eventuele
verschillen is de tekst van het Engelstalige persbericht altijd
leidend.
Contacts
Kiadis: Maryann
Cimino, Sr. Manager, Corporate Affairs Tel: +1 (617) 710-7305
m.cimino@kiadis.com |
LifeSpring Life Sciences
Communication:Leon Melens (Amsterdam)Tel: +31 538 16
427lmelens@lifespring.nl Optimum Strategic
Communications: Mary Clark, Supriya Mathur Tel: +44 203
950 9144 kiadis@optimumcomms.com |
About KiadisFounded in 1997,
Kiadis is building a fully integrated biopharmaceutical company
committed to developing innovative cell-based medicines for
patients with life-threatening diseases. With headquarters in
Amsterdam, The Netherlands, and offices and activities across the
United States, Kiadis is reimagining medicine by leveraging the
natural strengths of humanity and our collective immune system to
source the best cells for life.
Kiadis is listed on the regulated market of
Euronext Amsterdam and Euronext Brussels since July 2, 2015, under
the symbol KDS. Learn more at www.kiadis.com.
Forward Looking Statements
Certain statements, beliefs and opinions in this press release are
forward-looking, which reflect Kiadis' or, as appropriate, Kiadis'
officers' current expectations and projections about future events.
By their nature, forward-looking statements involve a number of
known and unknown risks, uncertainties and assumptions that could
cause actual results, performance, achievements or events to differ
materially from those expressed, anticipated or implied by the
forward-looking statements. These risks, uncertainties and
assumptions could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
regulation, competition and technology, can cause actual events,
performance, achievements or results to differ significantly from
any anticipated or implied development. Forward-looking statements
contained in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, Kiadis
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or projections,
or any change in events, conditions, assumptions or circumstances
on which these forward-looking statements are based. Neither Kiadis
nor its advisers or representatives nor any of its subsidiary
undertakings or any such person's officers or employees guarantees
that the assumptions underlying such forward-looking statements are
free from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the anticipated or
implied developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.